Sernova Corp T.SVA

Alternate Symbol(s): SEOVF

Healthcare Biotechnology

Sernova Corp. is a Canada-based clinical-stage biotechnology company, which is developing therapeutic cell technologies for chronic diseases, including insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. The Company is focused on developing a functional cure for insulin-dependent diabetes with its therapeutic cell technology lead asset, the Cell Pouch System, a novel implantable and scalable medical device with immune protected therapeutic cells. The Cell Pouch is a scalable, implantable medical device. The Cell Pouch is designed to create a vascularized organ-like environment for the transplantation and engraftment of therapeutic cells. Its regenerative medicine therapeutic approach is to provide cell therapies where the cells, transplanted within an organ-like vascularized implantable device, the Cell Pouch, generates proteins, hormones or factors released into the bloodstream for treatment of diseases.

TSX:SVA - Post by User

Sernova Corp > Why I think SVA is a good speculation

<< Previous

Bullboard Posts

Next >>

Comment by BioTeckon Jan 25, 2022 12:19am

231 Views

Post# 34356657

RE:Why I think SVA is a good speculation

Depends on the terms of the deal. If it isn't spectacular it'll fall hard. I know I'll be selling my position if I'm not happy and likely others will as well. If it is a good deal then the partner and terms will determine where we go. I personally think it'll be an OK deal and we get to see 3 dollars max is the markets don't continue to buckle but more likely 2 to 2.50 if we are lucky. Maybe less if we continue to drop to 1.20 again.

Stockfshr wrote:
Pouch: No fibrosis; donor cells work for two T1D patients so far

Cell strategy: Currently - donor cells; Better - Potential use of stem cells

Immune suppression strategy: Currently - drugs; Better? - Potential use of conformal coating through collaboration with University of Miami; Best? - Potential blue sky using AgeX UniverCyte gene editing
Confidential collaboration agreements with multiple pharmaceutical industry leaders
Potential competitors are stumbling making SVA more attractive: SANA, Sigilon
Huge diabetes T1D market. Additional potential markets: Hemophilia A; Thyroid disease. Tip of the iceberg?
Multiple shots on goal; steady progress.
Great management with proven individual success histories
Stock price recently shot up to $2.24 on hopes of a partnership deal on the anniversary of the last big news of collaborations. Imagine what could happen with actual news....
Thoughts?